<DOC>
	<DOC>NCT01044108</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC 0070-0002-0453 in overweight/obese, but otherwise healthy male and female volunteers. Selected subjects will continue in a follow-up period of up to 5 years.</brief_summary>
	<brief_title>A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers</brief_title>
	<detailed_description>Due to an unfavourable benefit-risk profile observed during the phase 1 trial for the obesity project, NN9161, Novo Nordisk has decided to terminate further clinical development.</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Nutrition Disorders</mesh_term>
	<criteria>FOR TRIAL PART 1, THE FOLLOWING APPLIES: Informed consent must be obtained before any trialrelated activities. Trialrelated activities are any procedures that would not have been performed during the normal management of the subject Overweight/obese males: Body Mass Index (BMI) between 27.0 to 39.0 kg/m2 Good general health FOR TRIAL PART 2, THE FOLLOWING APPLIES: Informed consent must be obtained before any trialrelated activities. Trialrelated activities are any procedures that would not have been performed during the normal management of the subject. Obese male and female subjects: Body Mass Index (BMI) between 30.0 to 39.0 kg/m2 Good general health. Aggressive diet attempts within the last 3 months Current or history of treatment with medications that may cause significant weight gain History of major depressive disorder or history of a suicide attempt or history of any suicidal behaviour History of eating disorders Any weight change of 5 kg (11 pounds) in the last 3 months Tobacco use History of alcoholism or drug/chemical abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>